WO2024085417A1 - S1pr1과 s1pr4에 대한 기능적 저해제로 작용하는 원형 탈모증의 예방 또는 치료용 약학적 조성물 - Google Patents
S1pr1과 s1pr4에 대한 기능적 저해제로 작용하는 원형 탈모증의 예방 또는 치료용 약학적 조성물 Download PDFInfo
- Publication number
- WO2024085417A1 WO2024085417A1 PCT/KR2023/012725 KR2023012725W WO2024085417A1 WO 2024085417 A1 WO2024085417 A1 WO 2024085417A1 KR 2023012725 W KR2023012725 W KR 2023012725W WO 2024085417 A1 WO2024085417 A1 WO 2024085417A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- alopecia areata
- preventing
- triazol
- diol
- Prior art date
Links
- 208000004631 alopecia areata Diseases 0.000 title claims abstract description 70
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 56
- 239000003112 inhibitor Substances 0.000 title claims abstract description 16
- 230000000694 effects Effects 0.000 claims abstract description 34
- 239000004480 active ingredient Substances 0.000 claims abstract description 21
- 102100025750 Sphingosine 1-phosphate receptor 1 Human genes 0.000 claims abstract description 18
- 102100029803 Sphingosine 1-phosphate receptor 4 Human genes 0.000 claims abstract description 18
- 101000693265 Homo sapiens Sphingosine 1-phosphate receptor 1 Proteins 0.000 claims abstract description 16
- 101000653757 Homo sapiens Sphingosine 1-phosphate receptor 4 Proteins 0.000 claims abstract description 16
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims description 61
- 238000011282 treatment Methods 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 16
- 230000003287 optical effect Effects 0.000 claims description 14
- 125000002947 alkylene group Chemical group 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 8
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 8
- 238000007911 parenteral administration Methods 0.000 claims description 7
- LTSWFNFQPMMTIG-UHFFFAOYSA-N 2-amino-2-[2-(1-decyltriazol-4-yl)ethyl]propane-1,3-diol Chemical compound NC(CO)(CO)CCC=1N=NN(C=1)CCCCCCCCCC LTSWFNFQPMMTIG-UHFFFAOYSA-N 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- HIGKZDYXDKYVRX-UHFFFAOYSA-N 2-amino-2-(1-dodecyltriazol-4-yl)propane-1,3-diol Chemical compound NC(CO)(CO)C=1N=NN(C=1)CCCCCCCCCCCC HIGKZDYXDKYVRX-UHFFFAOYSA-N 0.000 claims description 4
- IIQZVQBOBKCCOE-UHFFFAOYSA-N 2-amino-2-[2-(1-octyltriazol-4-yl)ethyl]propane-1,3-diol Chemical compound NC(CO)(CO)CCC=1N=NN(C=1)CCCCCCCC IIQZVQBOBKCCOE-UHFFFAOYSA-N 0.000 claims description 4
- OZWKYEUMDMXWQT-UHFFFAOYSA-N 2-amino-2-[2-[1-[2-(4-hexylphenyl)ethyl]triazol-4-yl]ethyl]propane-1,3-diol Chemical compound NC(CO)(CO)CCC=1N=NN(C=1)CCC1=CC=C(C=C1)CCCCCC OZWKYEUMDMXWQT-UHFFFAOYSA-N 0.000 claims description 4
- BNPOQDRRPWXBFQ-UHFFFAOYSA-N N-[2-(1-dodecyltriazol-4-yl)-1,3-dihydroxypropan-2-yl]acetamide Chemical compound C(C)(=O)NC(CO)(CO)C=1N=NN(C=1)CCCCCCCCCCCC BNPOQDRRPWXBFQ-UHFFFAOYSA-N 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 claims description 3
- GKJDPPDETDJPHL-UHFFFAOYSA-N N-[4-(1-decyltriazol-4-yl)-1-hydroxy-2-(hydroxymethyl)butan-2-yl]acetamide Chemical compound C(C)(=O)NC(CO)(CCC=1N=NN(C=1)CCCCCCCCCC)CO GKJDPPDETDJPHL-UHFFFAOYSA-N 0.000 claims description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 3
- 125000004450 alkenylene group Chemical group 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000005549 heteroarylene group Chemical group 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 3
- -1 sphingolipid compound Chemical class 0.000 abstract description 8
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 abstract description 5
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 abstract description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 24
- 239000000203 mixture Substances 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 201000004384 Alopecia Diseases 0.000 description 20
- 210000004209 hair Anatomy 0.000 description 18
- 208000024963 hair loss Diseases 0.000 description 17
- 230000003676 hair loss Effects 0.000 description 17
- 210000001185 bone marrow Anatomy 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 210000004698 lymphocyte Anatomy 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 241000282472 Canis lupus familiaris Species 0.000 description 9
- 108091006146 Channels Proteins 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 210000002865 immune cell Anatomy 0.000 description 7
- 238000009472 formulation Methods 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- AQDUJQUHCZDQBC-UHFFFAOYSA-N 1-azidodecane Chemical compound CCCCCCCCCCN=[N+]=[N-] AQDUJQUHCZDQBC-UHFFFAOYSA-N 0.000 description 5
- 235000008504 concentrate Nutrition 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 235000019439 ethyl acetate Nutrition 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 210000003780 hair follicle Anatomy 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000004761 scalp Anatomy 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 229950000971 baricitinib Drugs 0.000 description 3
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 210000000748 cardiovascular system Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 210000004709 eyebrow Anatomy 0.000 description 3
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 3
- 230000003779 hair growth Effects 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000003797 telogen phase Effects 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- CBRJPFGIXUFMTM-WDEREUQCSA-N 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one Chemical compound N1=CN=C(C2=C1NC=C2)N[C@@H]2CC[C@@H](N(C2)C(C=C)=O)C CBRJPFGIXUFMTM-WDEREUQCSA-N 0.000 description 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- HNNUBQWDWJNURV-UHFFFAOYSA-N 2-bromoethynyl-tri(propan-2-yl)silane Chemical group CC(C)[Si](C(C)C)(C(C)C)C#CBr HNNUBQWDWJNURV-UHFFFAOYSA-N 0.000 description 2
- 102100033875 3-oxo-5-alpha-steroid 4-dehydrogenase 2 Human genes 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000640851 Homo sapiens 3-oxo-5-alpha-steroid 4-dehydrogenase 2 Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 102000004257 Potassium Channel Human genes 0.000 description 2
- 101710155454 Sphingosine 1-phosphate receptor 1 Proteins 0.000 description 2
- 102100025749 Sphingosine 1-phosphate receptor 2 Human genes 0.000 description 2
- 101710155462 Sphingosine 1-phosphate receptor 2 Proteins 0.000 description 2
- 102100025747 Sphingosine 1-phosphate receptor 3 Human genes 0.000 description 2
- 101710155457 Sphingosine 1-phosphate receptor 3 Proteins 0.000 description 2
- 101710155458 Sphingosine 1-phosphate receptor 4 Proteins 0.000 description 2
- 102100029802 Sphingosine 1-phosphate receptor 5 Human genes 0.000 description 2
- 101710155451 Sphingosine 1-phosphate receptor 5 Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960003473 androstanolone Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960004039 finasteride Drugs 0.000 description 2
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 2
- 229960000556 fingolimod Drugs 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000004919 hair shaft Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229960003632 minoxidil Drugs 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 108020001213 potassium channel Proteins 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 229940018036 ritlecitinib Drugs 0.000 description 2
- 229940107889 rogaine Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- RXAHCVNYRABXLO-UHFFFAOYSA-N 1-azidooctane Chemical compound CCCCCCCCN=[N+]=[N-] RXAHCVNYRABXLO-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- ZIMGGGWCDYVHOY-UHFFFAOYSA-N 3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine Chemical group N=C1N(O)C(N)=CC(N2CCCCC2)=N1 ZIMGGGWCDYVHOY-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- OGWDOCZTSGRMDJ-UHFFFAOYSA-N CCCCCCCCCCN1C=C(N=N1)CCC(C)(C)N Chemical compound CCCCCCCCCCN1C=C(N=N1)CCC(C)(C)N OGWDOCZTSGRMDJ-UHFFFAOYSA-N 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- VRLNOUXWHPOGRK-UHFFFAOYSA-N N(=[N+]=[N-])CCCCCCCCC1=CC=CC=C1 Chemical compound N(=[N+]=[N-])CCCCCCCCC1=CC=CC=C1 VRLNOUXWHPOGRK-UHFFFAOYSA-N 0.000 description 1
- 229910017912 NH2OH Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002386 air freshener Substances 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 239000005441 aurora Substances 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- SBSLQTZCZRAGDL-UHFFFAOYSA-N bromo-tri(propan-2-yl)silane Chemical compound CC(C)[Si](Br)(C(C)C)C(C)C SBSLQTZCZRAGDL-UHFFFAOYSA-N 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003778 catagen phase Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000000212 effect on lymphocytes Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000009532 heart rate measurement Methods 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229940117382 propecia Drugs 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000033300 receptor internalization Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002336 repolarization Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000005212 secondary lymphoid organ Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- SZXXZSZVMCBALZ-UHFFFAOYSA-N tert-butyl n-(5-ethynyl-2,2-dimethyl-1,3-dioxan-5-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1(C#C)COC(C)(C)OC1 SZXXZSZVMCBALZ-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
Definitions
- the present invention relates to a composition for preventing or treating alopecia areata that acts as a functional inhibitor for S1PR1 and S1PR4. More specifically, the present invention relates to a composition for preventing or treating alopecia areata that acts as a functional inhibitor for S1PR1 and S1PR4 and does not cause cardiovascular disease side effects and alopecia areata. It relates to a pharmaceutical composition containing a sphingolipid compound that has a preventive or therapeutic effect.
- Hair loss is a condition in which hair falls out abnormally in large quantities. It is mainly caused by hair loss, but abnormal hair loss from beards, eyebrows, pubic hair, armpit hair, and other areas is also referred to as hair loss.
- Hair is produced in hair follicles, which are located in the dermis layer above the subcutaneous fat below the epidermis layer. Hair follicles are found in all parts of the body except the lips, palms, and soles, and new hair is created from the hair matrix at the base of the follicle. Living cells in the hair matrix proliferate and are pushed upward, and when these cells quickly dry out and die, they are compressed into a dense, hard mass that makes up the hair shaft.
- the hair shaft made of dead protein, is covered with a delicate layer (cuticle) of plate-like scales.
- the hair growth cycle consists of three stages: anagen, when hair grows most actively, followed by catagen, when hair deterioration begins, and telogen, when hair growth stops. there is.
- anagen when hair grows most actively
- catagen when hair deterioration begins
- telogen when hair growth stops. there is.
- the growth period of eyebrows and eyelashes lasts about 1 to 6 months, and the growth period of hair lasts about 2 to 6 years.
- about 50 to 100 strands of hair fall out every day at the end of the telogen period.
- Alopecia areata is a disease in which hair falls out in circular shapes. In the beginning, hair loss appears in one or two circular areas, but as it gets worse, circular hair loss occurs in several places at the same time or the hair loss areas become fused, and in addition to hair on the scalp, hair loss occurs in eyebrows or beards. Hair also appears to be lost.
- Alopecia areata is an autoimmune disease in which the immune system changes, causing immune cells to attack hair follicles and cause inflammation. It is known to be caused by stress and genetic causes. Less than 10% of patients with alopecia areata may be accompanied by atopic dermatitis, thyroid disease, and other autoimmune diseases of the malignant type. Although it occurs in both men and women and at all ages, it is the most common disease among children and young adults, affecting the overall population. It has a prevalence of about 1-2%.
- the representative treatment for alopecia areata is steroid medication.
- steroid injections, steroid medications, and immunosuppressants have been used as treatments.
- steroid treatment initially shows some effectiveness, long-term treatment can actually worsen symptoms or cause scalp inflammation, scalp depression, etc. It can cause side effects such as high blood pressure, weight gain, heartburn, and gastritis, and has a tendency to relapse.
- Minoxidil is a drug that induces hair growth by increasing blood flow through vasodilation and supplying nutrients to the hair roots. It is known to be particularly effective in alleviating hair loss symptoms in the whorl area, and medicines that use it as an active ingredient are It is marketed under the brand name Rogaine (trade name of Pharmacia & Upjohn Company). Rogaine is known to reduce hair loss by up to 10% and promote hair growth in men suffering from male pattern baldness, but it must be applied externally directly to the scalp, used regularly over a long period of time, and should not be used in areas other than the whorl of hair. It has the disadvantage of not having a very good effect on hair loss.
- a medicine using finasteride as an active ingredient is marketed under the brand name Propecia (trade name of Merck & Co., Inc.). It is a pill for oral administration and inhibits the function of type II 5 ⁇ -reductase, thereby reducing testosterone to dihydrotestosterone. It is known to suppress hair loss by preventing its conversion to (Dihydrotestosterone, DHT), but this also requires continuous and regular administration, and in some patients, it causes side effects such as decreased libido and erectile dysfunction. It can only be used for adult men. However, there is a problem that it is not effective for alopecia areata.
- Olumiant (ingredient name: Baricitinib), an oral JAK inhibitor known to treat rheumatoid arthritis, received FDA approval in June 2022 as the third hair loss drug and the first systemic treatment for alopecia areata.
- Pfizer also announced efficacy data similar to Olumiant after completing phase 3 trials of PF-06651600 (ingredient name: Ritlecitinib), a type of JAK inhibitor, and was recently approved by the FDA.
- PF-06651600 oral componentcitinib
- JAK inhibitors increase the risk of heart attack, stroke, and cancer, and there is a continued need for the development of safe medicines with excellent alopecia areata treatment efficacy and low toxicity and side effects.
- the compound according to the present invention binds specifically to S1PR1 and S1PR4 receptors and acts as a functional inhibitor (antagonist)
- the present invention was completed by confirming that it is effective in preventing or treating alopecia.
- the purpose of the present invention is to provide a pharmaceutical composition containing as an active ingredient a compound that has pharmacological activity for preventing or treating alopecia areata and does not cause cardiovascular disease side effects.
- the present invention aims to provide a method for preventing or treating alopecia areata, comprising administering the composition or the active ingredient in the composition to a subject in need thereof.
- the purpose of the present invention is to provide the use of the composition or the active ingredient in the composition for the prevention or treatment of alopecia areata.
- the purpose of the present invention is to provide the use of the composition or the active ingredient in the composition for the production of a drug for the prevention or treatment of alopecia areata.
- the present invention provides a pharmaceutical composition for the prevention or treatment of alopecia areata comprising a compound represented by the following formula (1), an optical isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient:
- R 1 is hydrogen
- R 2 is hydrogen or an acetyl group
- X is a single bond, C 2 alkylene, or C 2 alkenylene
- A is a 5-membered heteroarylene ring containing 3 N atoms
- B is C 2-11 linear or branched alkylene
- C is a single bond or phenylene
- D is selected from the group consisting of hydrogen, phenyl and C 1-6 alkyl.
- the R 2 may be hydrogen.
- the X may be C 2 alkylene.
- the B may be C 2-11 linear alkylene.
- the compound represented by Formula 1 may be any one compound selected from the group of compounds below.
- the compound represented by Formula 1 may be a compound represented by Formula 2 below (hereinafter referred to as 'NXC736').
- the pharmaceutical composition according to the present invention may be a formulation for oral administration or a formulation for parenteral administration.
- the pharmaceutical composition according to the present invention may further include one or more other therapeutic agents suitable for the treatment of alopecia areata.
- composition according to the present invention can act as a functional inhibitor for S1PR1 and S1PR4.
- the pharmaceutical composition according to the present invention can be expected to have the effect of not causing cardiovascular disease side effects.
- the present invention also provides a composition comprising the compound represented by Formula 1, an optical isomer thereof, or a salt thereof.
- the present invention also provides a method for preventing or treating alopecia areata, comprising administering the composition or the active ingredient in the composition to a subject in need thereof.
- the present invention also provides the use of the composition or the active ingredient in the composition for the prevention or treatment of alopecia areata.
- the present invention also provides the use of the composition or the active ingredient in the composition for the production of a drug for the prevention or treatment of alopecia areata.
- the pharmaceutical composition according to the present invention acts as a functional inhibitor for S1PR1 and S1PR4 and has an effect in preventing or treating alopecia areata.
- the pharmaceutical composition according to the present invention acts as a functional inhibitor for S1PR1 and S1PR4 among S1P receptor subtypes (S1P1, S1P2, S1P3, S1P4 and S1P5), and has an effect in preventing or treating alopecia areata and cardiovascular diseases. It is effective without causing side effects.
- Figure 1 is a graph showing changes in the number of total T cells and T cell subtypes in mice after oral administration of NXC736 (3 mg/kg/day).
- Figure 2 is a graph showing changes in the number of total T cells and T cell subtypes in rats after oral administration of NXC736 (10 mg/kg/day).
- Figure 3 shows the results of comparing the AA lesion area according to oral administration of control group and NXC736 (30 mg/kg/day) in alopecia areata mouse model C3H/HeJ.
- Figure 4 shows the results of comparing disease free ratio according to oral administration of control group and NXC736 (30mg/kg/day) in alopecia areata mouse model C3H/HeJ.
- Figure 5 shows the results of comparing the effect of suppressing alopecia areata induced by oral administration of the control group and NXC736 (30 mg/kg/day) in the alopecia areata mouse model C3H/HeJ.
- Figure 6 is a table evaluating the effect of NXC736 (1, 3, 10, 30 ⁇ M) on HEK293 cells overexpressing the hERG gene.
- Figure 7 is a graph showing the heart rate measurement results of beagle dogs after oral administration of NXC736 (12.5, 25, 50 mg/kg).
- Prevention in the present invention refers to all actions that suppress or delay the onset of a target disease by administering an active ingredient to an individual.
- Treatment in the present invention refers to any act of administering an active ingredient to an individual to improve or benefit the symptoms of the target disease.
- the pharmaceutical composition for preventing or treating alopecia areata contains a compound represented by the following formula (1), an optical isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.
- R 1 is hydrogen
- R 2 is hydrogen or an acetyl group
- X is a single bond, C 2 alkylene, or C 2 alkenylene
- A is a 5-membered heteroarylene ring containing 3 N atoms
- B is C 2-11 linear or branched alkylene
- C is a single bond or phenylene
- D is selected from the group consisting of hydrogen, phenyl and C 1-6 alkyl.
- the R 2 may be hydrogen.
- the X may be C 2 alkylene.
- the B may be C 2-11 linear alkylene.
- the compound represented by Formula 1 may be any one compound selected from the group of compounds below.
- the compound represented by Formula 1 is 2-amino-2-(2-(1-decyl-1H-1,2,3-triazol-4-yl)ethyl)propane, which is a compound represented by Formula 2 below. It may be -1,3-diol (aka, NXC736).
- the compound represented by Formula 1 can be used in the form of a pharmaceutically acceptable salt.
- the salt may be an acid addition salt formed from a pharmaceutically acceptable free acid.
- the pharmaceutical composition according to the present invention not only contains the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient, but also contains substances selected from solvates, optical isomers, hydrates, etc. that can be prepared therefrom. It can be included as an active ingredient.
- the compound represented by Formula 1, its optical isomer, or its pharmaceutically acceptable salt is a pharmaceutically effective amount, for example, any amount within 0.1 to 99.9% by weight relative to the total weight of the pharmaceutical composition. may be included.
- compositions for the prevention or treatment of alopecia areata containing the compound represented by Formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient are preparations for oral administration and other types of pharmaceutical compositions to the extent that they exhibit pharmacological activity.
- the formulation can be changed.
- Preparations for oral administration may be in the form of troches, lozenges, tablets, aqueous suspensions, oily suspensions, powders, granules, emulsions, hard capsules, soft capsules, syrups, or elixirs. It is not limited to this.
- binders such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose, or gelatin; Excipients such as dicalcium phosphate; disintegrants such as corn starch or sweet potato starch; Lubricants such as magnesium stearate, calcium stearate, sodium stearyl fumarate, or polyethylene glycol wax; sweetener; air freshener; syrup; etc. can be used.
- a liquid carrier such as fatty oil can be additionally used.
- a pharmaceutical composition for the prevention or treatment of alopecia areata containing the compound represented by Formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient may be formulated and used in various formulations suitable for parenteral administration.
- Preparations for parenteral administration include, but are not limited to, injections, suppositories, powders for respiratory inhalation, aerosols for sprays, ointments, powders for application, oils, and creams.
- non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate.
- the pharmaceutical composition according to the present invention is formulated as an injection solution
- the pharmaceutical composition is mixed in water with a stabilizer or buffer to prepare a solution or suspension and formulated for unit administration in ampoules or vials. You can.
- a propellant, etc. may be mixed with additives to disperse the water-dispersed concentrate or wet powder.
- the pharmaceutical composition according to the present invention is formulated into ointments, creams, etc., animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc, oxidation It can be formulated using zinc, etc. as a carrier.
- the pharmaceutical composition according to the present invention may further include one or more other therapeutic agents suitable for the treatment of alopecia areata.
- One or more other therapeutic agents suitable for the treatment of alopecia areata may be administered together or separately. When administered separately, they may be administered simultaneously or sequentially in any order. The dosage and timing of administration of the compound of Formula 1 or a pharmaceutically acceptable salt thereof and other therapeutic agents may be selected to achieve the desired combination therapeutic effect.
- composition according to the present invention may further include a pharmaceutically acceptable carrier.
- pharmaceutically acceptable means that the compound does not irritate the organism upon administration and does not inhibit the biological activity and properties of the administered compound, as is commonly used in the pharmaceutical field.
- the type of carrier is not particularly limited, and any carrier commonly used in the art can be used.
- Non-limiting examples of carriers include saline solution, sterile water, Ringer's solution, buffered saline solution, albumin injection solution, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, maltodextrin, glycerol, ethanol, etc. there is. These may be used alone or in combination of two or more types.
- additives such as excipients, diluents, antioxidants, buffers, or bacteriostatic agents may be added to the pharmaceutical composition according to the present invention.
- fillers, extenders, wetting agents, disintegrants, dispersants, surfactants, binders, or lubricants may be additionally added to the pharmaceutical composition according to the present invention.
- the pharmacologically effective amount and dosage for the human body of the pharmaceutical composition according to the present invention may vary depending on the formulation method, administration method, administration time, and/or administration route of the pharmaceutical composition.
- the above dosage depends on the type and degree of response to be achieved by administration of the pharmaceutical composition, the type of subject to be administered, age, weight, general health status, symptoms or degree of disease, gender, diet, excretion, and the subject. It may vary depending on various factors including ingredients of other compositions such as drugs used simultaneously or at the same time, and similar factors widely known in the pharmaceutical field.
- the administration route and administration method of the pharmaceutical composition according to the present invention may be independent, and there is no particular limitation in the method.
- the pharmaceutical composition according to the present invention can be administered by any route and method of administration as long as the active ingredient can reach the target area.
- the pharmaceutical composition according to the present invention can be administered by oral or parenteral administration.
- parenteral administration methods include intravenous administration, intraperitoneal administration, intramuscular administration, transdermal administration, or subcutaneous administration.
- the pharmaceutical composition according to the present invention may be applied to the diseased area, sprayed, or inhaled, but is not limited thereto.
- the pharmaceutical composition according to the present invention can be used for the treatment of alopecia areata in a subject in need thereof.
- the type of subject is not particularly limited, but may be a mammal, preferably a human.
- the present invention provides a composition comprising the compound represented by Formula 1, an optical isomer thereof, or a salt thereof.
- the present invention provides a prototype comprising the step of administering the compound represented by Formula 1, or an optical isomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the same to an individual in need thereof.
- the entity may be a human or a non-human animal.
- the present invention provides a use of the compound represented by Formula 1, or an optical isomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the same, for the prevention or treatment of alopecia areata. .
- the present invention provides a compound represented by Formula 1, or an optical isomer or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the same for the production of a drug for the prevention or treatment of alopecia areata. Provides a purpose.
- the S1PR1 receptor mainly exists in lymphocytes and is mainly responsible for controlling the release of lymphocytes from immune cells.
- the S1PR4 receptor is also present in lymphocytes and not only acts on immune cell trafficking, but also acts on T cell regulation and is involved in inflammatory reactions. Therefore, the compound of the present invention not only acts as a functional inhibitor of the S1PR1 receptor to inhibit the release of lymphocytes, but also acts on S1PR4 and exhibits an effective anti-inflammatory effect, thereby preventing or treating alopecia areata.
- the compound of the present invention has the effect of preventing or treating alopecia areata by specifically binding to S1PR1 and S1PR4 and then acting as a functional antagonist for this receptor through a mechanism of entering the cell and eliminating them.
- the pharmaceutical composition according to the present invention acts as a functional inhibitor for S1PR1 and S1PR4 and may not cause cardiovascular disease side effects.
- the compound represented by Formula 1, its optical isomer, or its pharmaceutically acceptable salt acts as a functional inhibitor for S1PR1 and S1PR4 and can prevent or treat alopecia areata without causing cardiovascular disease side effects.
- the compound represented by Formula 1 of the present invention can be prepared through the method described in Korean Patent Publication No. 10-2017-0087813, and the method is the same as the Examples described below.
- the method for producing the compound represented by Chemical Formula 1 of the present invention is not limited to this, and may be produced by a modified method within the range that can be modified by a person skilled in the art.
- Step 1 of tert-butyl(2,2-dimethyl-5-((triisopropylsilyl)buta-1,3-dyne-1-yl)-1,3-dioxan-5-yl)carbamate manufacturing
- This concentrate was diluted with ethyl acetate and washed with brine, and the organic layer was dried with MgSO 4 , filtered under vacuum, and concentrated. This was purified by flash column chromatography (hexane/EtOAc, 7:1) to prepare the target compound as a white solid (1.85 g, 4.25 mmol, 87 %).
- Step 2 tert-Butyl(5-((1-decyl-1H-1,2,3-triazol-4-yl)ethynyl)-2,2-dimethyl-1,3-dioxan-5-yl )Manufacture of carbamate
- step 1 The compound prepared in step 1 (334 mg, 1.20 mmol) was dissolved in anhydrous DMF (12 mL), 1-azidodecane (339 mg, 1.86 mmol), CuI (114 mg, 0.60 mmol), and DIPEA (N , N-Diisopropylethylamine) (0.63 mL, 3.6 mmol) and AgF (182 mg, 1.44 mmol) were added. After stirring the reaction mixture at room temperature for 12 hours, the reaction was quenched with saturated NH 4 Cl, extracted twice with ethyl acetate, and the organic layer extract was washed with saturated NH 4 Cl and brine. This was dried with MgSO 4 and concentrated under reduced pressure. This concentrate was purified by flash column chromatography (hexane/EtOAc, 6:1) to prepare the target compound as a white solid (439 mg, 0.95 mmol, 79%).
- Step 3 tert-Butyl(5-(2-(1-decyl-1H-1,2,3-triazol-4-yl)ethyl)-2,2-dimethyl-1,3-dioxane-5- 1) Carbamate
- Step 4 Preparation of 2-amino-2-(2-(1-decyl-1H-1,2,3-triazol-4-yl)ethyl)propane-1,3-diol
- the target compound was prepared in the same manner as in Example 1, except that 1-azidooctane was used instead of 1-azidodecane.
- the target compound was prepared in the same manner as in Example 1, except that 1-(2-azidoethyl)-4-hexylbenzene was used instead of 1-azidodecane.
- Bromotriisopropylsilane was used instead of 2-bromo-1-triisopropylsilyl acetylene used in Step 1 of Example 1, and 1-aza was used instead of 1-azidodecane in Step 2.
- the target compound was prepared in the same manner as Example 1 except for using idododecane (1-azidodoedcane).
- the temperature of the THF (5 mL) solution containing the compound prepared in step 2 of Example 1 was lowered to -78°C, and then the THF solution (0.3 mmol) containing LAH (lithium aluminum hydride) dissolved in it was slowly added dropwise. After stirring at 0°C for three hours, the reaction was quenched with water and extracted twice with CH 2 Cl 2 . The organic layer was washed with brine, dried over MgSO 4 and concentrated in vacuo. The concentrate was purified by flash column chromatography (CH 2 Cl 2 /MeOH, 20:1) to prepare the target compound as a white solid. Thereafter, the target compound was prepared in the same manner as the reaction process in Step 4 of Example 1. (24 mg, 0.074 mmol, 74%)
- the target compound was prepared in the same manner as in Example 1, except that instead of using 1-azidodecane used in Step 2 of Example 1, 8-azidooctylbenzene was used.
- the target compound was prepared by using the compound prepared in Example 1 as a starting material and performing a similar acetylation reaction as in Example 7.
- Example 7 Using the compound prepared in Example 3 as a starting material, the target compound was prepared in a similar manner to the acetylation reaction performed in Example 7.
- FTY720 (Fingolimod) reversibly captures some of the lymphocytes in the lymph nodes or bone marrow, sequestering them in secondary lymphoid organs and inhibiting their entry into the central nervous system, or reducing the number of lymphocytes circulating in the bloodstream to activate them reaching the brain. It is a treatment for multiple sclerosis with a mechanism of action that reduces the number of lymphocytes.
- NXC736, which acts on the S1P receptor, also has an effect on lymphocyte reduction the effect of NXC736 on immune cells was evaluated.
- NXC736 was administered once at 3 mg/kg/day to C57BL/6 mice (Daehan Biolink (DBL), control group 4, test group 18), peripheral blood flow (PB) and bone marrow (BM) marrow) into T cells (using anti-mouse CD3 ⁇ -PE/cyanine7 antibody), CD4 T cells (using anti-mouse CD4-FITC antibody), and CD8 T cells (using anti-mouse CD8a-PerCP antibody). It was classified and measured.
- T cells in the peripheral bloodstream (PB), by administering 3 mg/kg of NXC736, T cells, CD4 T cells, and CD8 T cells decreased to 40.6 to 41.6%, 16.4 to 17.6%, and 5.9 to 9.3%, respectively, 4 hours later. It was confirmed that it was reduced to . In the case of T cells, the decrease was maintained until 12 hours, and then gradually recovered, reaching 88.9% at 36 hours.
- T cells were found to increase to 120 to 135% after 4 hours and to 118 to 131% after 24 hours by administration of 3 mg/kg of NXC736. This is believed to be a phenomenon that occurs when receptor internalization occurs by NXC736 and T cell release is suppressed.
- NXC736 After administration of 3 mg/kg of NXC736, the number of T cells in the peripheral bloodstream (PB) steadily decreased for up to 12 hours, and the inhibitory effect was maintained to some extent until 24 hours before recovery. In conclusion, it was confirmed that administration of NXC736 resulted in a decrease in the number of lymphocytes circulating in the bloodstream and an immunosuppressive effect.
- NXC736 was administered orally once at 10 mg/kg/day to SD rats (Daehan Biolink (DBL), 3 in the control group, 15 in the test group) in Experimental Example 1.
- the same antibody was used to classify and measure T cells, CD4 T cells, and CD8 T cells in the peripheral bloodstream (PB) and bone marrow (BM).
- PB peripheral bloodstream
- BM bone marrow
- measurements were made using a flow cytometer (FC500, Beckman coulter) at 0, 4, 8, 12, 24, 36, and 48 hours after administration of the test substance, and analysis was performed using FlowJoTM V10 (Flowjo, LLC).
- the numbers of T cells, CD4 T cells, and CD8 T cells were measured and expressed as % of control based on time 0.
- T cells were rapidly reduced in the peripheral bloodstream (PB) for up to 4 hours after administration of NXC736. It was confirmed that the immunosuppressive effect was maintained for up to 24 hours by administration of 10 mg/kg of NXC736.
- PB peripheral bloodstream
- BM bone marrow
- NXC736 exhibits an immunosuppressive effect by reducing the number of lymphocytes in the peripheral bloodstream (PB) after oral administration.
- PB peripheral bloodstream
- BM bone marrow
- This effect is believed to be related to the mechanism by which NXC736 acts as a functional antagonist on the S1P receptor present in lymph nodes, bone marrow (BM), etc., thereby suppressing lymphocyte release.
- C3H/HeJ mice are experimental animals that naturally develop alopecia areata as they age. Lymph node cells obtained from C3H/HeJ mice over 20 weeks of age, which naturally develop alopecia areata, are proliferated to produce alopecia areata at 10 to 16 weeks of age without causing alopecia areata. was injected into C3H/HeJ mice to induce alopecia areata.
- Conditions for the animal breeding room include a temperature of 23 ⁇ 3°C, relative humidity of 50 ⁇ 10%, and day and night maintained at 12-hour intervals. Experimental animals are raised in isolation boxes (ThreeShine), and food and drinking water for experimental animals are provided. It was paid freely.
- mice were divided into two groups, a control group (sterilized distilled water administration group) and a NXC736 administration experimental group, and five C3H/HeJ mice per group were randomly assigned. Lymph node cells were proliferated to produce C3H/HeJ mice aged 10 to 16 weeks that did not cause alopecia areata. From the time of injection into HeJ mice, 30 mg/kg of NXC736 was administered to the NXC736 administration group, and the same volume of sterilized distilled water to the control group was orally administered once a day at the same time for 12 weeks, and then the area of alopecia areata (AA lesion area) and disease-free area were measured. Disease free ratio was measured at two-week intervals.
- the area of the circular hair loss lesion was measured using the Image J program (Version 1.44p) after taking a photograph.
- the AA lesion area was about 80% in the control group and about 10% in the NXC736 administration group, and the AA lesion area in the NXC736 administration group was significant compared to the control group. It was confirmed that the enemy was noticeably less.
- the disease-free rate was defined as the proportion of mice administered the drug and not showing hair loss symptoms at a specified time point.
- NXC736 was applied to HEK-293 cells (Aurora Biomed Inc., Canada), which stably expressed the hERG potassium ion channel, to evaluate its effect on hERG channel currents. NXC736 was set at concentrations of 1, 3, 10, and 30 ⁇ M.
- hERG channel currents were measured, cells measured over 500 pA and less than 3000 pA at the -50 mV repolarization step were selected, and then placed in an external water bath solution (137mM NaCl, 4mM KCl, 10mM HEPES, 1 After treatment with test substances of each concentration dissolved in (mM MgCl 2 , 10 mM D-glucose, 1.8 mM CaCl 2 , pH 7.4) for 9 minutes, the channel current was recorded through the Notocord program (Notocord System, France).
- the compensated suppression rate (%) of hERG channel currents was 82.62 ⁇ 7.31%, and the K + ion channel inhibition ability (IC50 ) was calculated to be 12.94 ⁇ M (Hill coefficient: 1.527).
- NXC736 was orally administered to four unanesthetized and unrestrained male beagle dogs (ORIENTBIO Inc., Republic of Korea) implanted with remote transmitters. Afterwards, the heart rate of four beagle dogs was measured to evaluate the effect of NXC736 on the cardiovascular system, and the presence of abnormal symptoms was visually confirmed.
- the heart rate of the beagle dog is specifically measured at 0 hours (hours) before administration of the test substance, 0.5 hours (hours), 1 hour (hours), 2 hours (hours), 3 hours (hours), 4 hours (hours) after administration of the test substance, Measurements were made after 6 hours, 8 hours, 12 hours, and 24 hours.
- a pharmaceutical composition containing a compound, an optical isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient acts as a functional inhibitor for S1PR1 and S1PR4 and has an effect in preventing or treating alopecia areata.
- the pharmaceutical composition according to the present invention acts as a functional inhibitor for S1PR1 and S1PR4 among S1P receptor subtypes (S1P1, S1P2, S1P3, S1P4 and S1P5), and has an effect in preventing or treating alopecia areata and cardiovascular diseases. It was confirmed that it was effective without causing side effects.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
- 제1항에 있어서,상기 R2는 수소인 것을 특징으로 하는 원형 탈모증의 예방 또는 치료용 약학적 조성물.
- 제1항에 있어서,상기 X는 C2 알킬렌인 것을 특징으로 하는 원형 탈모증의 예방 또는 치료용 약학적 조성물.
- 제1항에 있어서,상기 B는 C2-11의 직쇄 알킬렌인 것을 특징으로 하는 원형 탈모증의 예방 또는 치료용 약학적 조성물.
- 제1항에 있어서,상기 화학식 1로 표시되는 화합물이 하기 화합물 군으로부터 선택되는 어느 하나의 화합물인 것을 특징으로 하는 원형 탈모증의 예방 또는 치료용 약학적 조성물:(1) 2-아미노-2-(2-(1-데실-1H-1,2,3-트라이아졸-4-일)에틸)프로판-1,3-다이올;(2) 2-아미노-2-(2-(1-옥틸-1H-1,2,3-트라이아졸-4-일)에틸)프로판-1,3-다이올;(3) 2-아미노-2-(2-(1-(4-헥실펜에틸)-1H-1,2,3-트라이아졸-4-일)에틸)프로판-1,3-다이올;(4) 2-아미노-2-(1-도데실-1H-1,2,3-트라이아졸-4-일)프로판-1,3-다이올;(5) (E)-2-아미노-2-(1-데실-1H-1,2,3-트라이아졸-4-일)바이닐-1,3-다이올;(6) 2-아미노-2-(2-(1-(8-페닐옥틸)-1H-1,2,3-트라이아졸부틸-4-일)에틸)프로판-1,3-다이올;(7) N-(2-(1-도데실-1H-1,2,3-트리아졸-4-일)-1,3-디하이드로옥시프로판-2-일)아세트아미드;(8) N-(4-(1-데실-1H-1,2,3-트리아졸-4-일)-1-히드록시-2-(히드록시메틸)부탄-2-일)아세트아미드; 및(9) N-(4-(1-(4-헥실펜에틸)-1H-1,2,3-트리아졸-4-일)-1-히드록시-2-(히드록시메틸)부탄-2-일)아세트아미드.
- 제1항 내지 제6항 중 어느 한 항에 있어서,상기 약학적 조성물이 경구 투여용 제제 또는 비경구 투여용 제제인 것을 특징으로 하는 원형 탈모증의 예방 또는 치료용 약학적 조성물.
- 제1항 내지 제6항 중 어느 한 항에 있어서,상기 약학적 조성물이 원형 탈모증의 치료에 적합한 하나 이상의 다른 치료제를 추가로 포함하는 것을 특징으로 하는 원형 탈모증의 예방 또는 치료용 약학적 조성물.
- 제1항 내지 제6항 중 어느 한 항에 따른 약학적 조성물은 S1PR1 및 S1PR4에 대한 기능적 저해제로 작용하는 것을 특징으로 하는 원형 탈모증의 예방 또는 치료용 약학적 조성물.
- 제9항에 있어서,상기 약학적 조성물은 심혈관 질환 부작용을 야기하지 않는 것을 특징으로 하는 원형 탈모증의 예방 또는 치료용 약학적 조성물.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3213748A CA3213748A1 (en) | 2022-10-21 | 2023-08-28 | Pharmaceutical composition for preventing or treating alopecia areata acting as a functional antagonist for s1pr1 and s1pr4 |
CN202380010914.3A CN118234492A (zh) | 2022-10-21 | 2023-08-28 | 具有针对s1pr1和s1pr4的功能性抑制剂作用的用于预防或治疗圆形脱发症的药物组合物 |
AU2023248144A AU2023248144B2 (en) | 2022-10-21 | 2023-08-28 | Pharmaceutical composition for preventing or treating alopecia areata acting as a functional antagonist for s1pr1 and s1pr4 |
US18/474,522 US11957665B1 (en) | 2022-10-21 | 2023-09-26 | Pharmaceutical composition for preventing or treating alopecia areata acting as a functional antagonist for S1PR1 and S1PR4 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263418071P | 2022-10-21 | 2022-10-21 | |
US63/418,071 | 2022-10-21 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/474,522 Continuation US11957665B1 (en) | 2022-10-21 | 2023-09-26 | Pharmaceutical composition for preventing or treating alopecia areata acting as a functional antagonist for S1PR1 and S1PR4 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024085417A1 true WO2024085417A1 (ko) | 2024-04-25 |
Family
ID=86762605
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2023/012725 WO2024085417A1 (ko) | 2022-10-21 | 2023-08-28 | S1pr1과 s1pr4에 대한 기능적 저해제로 작용하는 원형 탈모증의 예방 또는 치료용 약학적 조성물 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR102541577B1 (ko) |
WO (1) | WO2024085417A1 (ko) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4139619A (en) | 1976-05-24 | 1979-02-13 | The Upjohn Company | 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth |
US4596812A (en) | 1976-05-24 | 1986-06-24 | The Upjohn Company | Methods and solutions for treating male pattern alopecia |
KR20100015857A (ko) * | 2007-04-23 | 2010-02-12 | 노파르티스 아게 | S1p 수용체 조절 활성을 갖는 프탈라진 및 이소퀴놀린 유도체 |
KR20170087813A (ko) | 2016-01-20 | 2017-07-31 | 서울대학교산학협력단 | 신규한 헤테로방향족 고리 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 s1p 수용체 관련 질환의 예방 또는 치료용 약학적 조성물 |
KR20180110499A (ko) * | 2017-03-29 | 2018-10-10 | 재단법인 아산사회복지재단 | S1pr4를 타겟으로 하는 비알코올성 지방간염 예방 또는 치료용 조성물 |
KR20210105102A (ko) * | 2020-02-18 | 2021-08-26 | 재단법인 아산사회복지재단 | 천식 또는 기관지염 예방 또는 치료용 약학적 조성물 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1673349T3 (da) * | 2003-09-22 | 2010-10-25 | S Bio Pte Ltd | Benzimidazolderivater: fremstilling og farmaceutiske anvendelser |
AU2021205465A1 (en) * | 2020-01-06 | 2022-07-14 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
-
2022
- 2022-11-03 KR KR1020220145210A patent/KR102541577B1/ko active IP Right Grant
-
2023
- 2023-08-28 WO PCT/KR2023/012725 patent/WO2024085417A1/ko unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4139619A (en) | 1976-05-24 | 1979-02-13 | The Upjohn Company | 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth |
US4596812A (en) | 1976-05-24 | 1986-06-24 | The Upjohn Company | Methods and solutions for treating male pattern alopecia |
KR20100015857A (ko) * | 2007-04-23 | 2010-02-12 | 노파르티스 아게 | S1p 수용체 조절 활성을 갖는 프탈라진 및 이소퀴놀린 유도체 |
KR20170087813A (ko) | 2016-01-20 | 2017-07-31 | 서울대학교산학협력단 | 신규한 헤테로방향족 고리 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 s1p 수용체 관련 질환의 예방 또는 치료용 약학적 조성물 |
KR20180110499A (ko) * | 2017-03-29 | 2018-10-10 | 재단법인 아산사회복지재단 | S1pr4를 타겟으로 하는 비알코올성 지방간염 예방 또는 치료용 조성물 |
KR20210105102A (ko) * | 2020-02-18 | 2021-08-26 | 재단법인 아산사회복지재단 | 천식 또는 기관지염 예방 또는 치료용 약학적 조성물 |
Non-Patent Citations (1)
Title |
---|
KEI HASHIMOTO: "NLRP3 inflammasome activation contributes to development of alopecia areata in C3H/HeJ mice", EXPERIMENTAL DERMATOLOGY, BLACKWELL MUNSGAARD, COPENHAGEN; DK, vol. 31, no. 2, 1 February 2022 (2022-02-01), COPENHAGEN; DK , pages 133 - 142, XP093162853, ISSN: 0906-6705, DOI: 10.1111/exd.14432 * |
Also Published As
Publication number | Publication date |
---|---|
KR102541577B1 (ko) | 2023-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014163219A1 (ko) | 신규한 파이토스핑고신-1-포스페이트 유도체, 그 제조방법, 및 그것을 포함하는 탈모의 예방, 치료, 또는 육모용 조성물 | |
WO2020256477A1 (ko) | 암 세포 성장을 억제하는 피리미딘 유도체 및 이의 의약 용도 | |
WO2020106119A1 (en) | Pharmaceutical composition comprising histone deacetylase 6 inhibitors | |
WO2024085417A1 (ko) | S1pr1과 s1pr4에 대한 기능적 저해제로 작용하는 원형 탈모증의 예방 또는 치료용 약학적 조성물 | |
WO2023043197A1 (ko) | 신규한 카나비디올 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물 | |
WO2009148280A2 (ko) | 바이러스 억제제로서 유용한 디아릴 헤파토노이드계 화합물 | |
WO2019231261A1 (ko) | 신규 바이페닐 유도체 화합물 및 이의 용도 | |
WO2019182322A1 (ko) | 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물 | |
WO2021025448A1 (ko) | 히스톤 아세틸트렌스퍼라제 p300 억제용 신규 화합물 및 이를 포함하는 항섬유화 조성물 | |
WO2022025636A1 (ko) | Mglur5 및 5-ht2a 수용체의 이중 조절제 및 이의 용도 | |
WO2022149925A1 (ko) | 신규한 트립토판 수산화효소 저해제 및 이의 용도 | |
WO2013015661A2 (en) | Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide | |
WO2023224362A1 (ko) | S1pr1과 s1pr4에 대한 기능적 저해제로 작용하는 방사선 유발 폐 섬유증의 예방 또는 치료용 약학적 조성물 | |
AU2022448086B2 (en) | Pharmaceutical composition for preventing or treating inflammatory bowel disease acting as a functional antagonist for s1pr1 and s1pr4 | |
WO2023043024A1 (en) | Pharmaceutical composition for preventing or treating interstitial fibrosis and tubular atrophy as a functional antagonist for s1pr1 and s1pr4 | |
WO2023239171A1 (ko) | 신규 화합물 및 이의 용도 | |
WO2010143803A2 (en) | New nicotinamide derivatives with anti-androgen effects, processes of preparing, and antiandrogens comprising the same | |
WO2023042996A1 (en) | Pharmaceutical composition for preventing or treating focal segmental glomerulosclerosis acting as a functional antagonist for s1pr1 and s1pr4 | |
WO2021054510A1 (ko) | 셀레노사마필린 a를 유효성분으로 포함하는 유방암 예방 및 치료용 조성물 | |
WO2020040326A1 (ko) | 페닐아세트산 유도체 및 이를 유효성분으로 함유하는 자가면역질환 예방 또는 치료용 조성물 | |
US11957665B1 (en) | Pharmaceutical composition for preventing or treating alopecia areata acting as a functional antagonist for S1PR1 and S1PR4 | |
WO2023287241A1 (ko) | 신규한 벤즈옥사졸아민 유도체 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 | |
WO2024049236A1 (ko) | 키랄 감마 락탐 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 제조방법 | |
WO2024128335A1 (ko) | 골질환의 예방 또는 치료용 약학 조성물 | |
WO2020076129A1 (en) | Pharmaceutical composition comprising histone deacetylase inhibitor and methotrexate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2023248144 Country of ref document: AU Date of ref document: 20230828 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023020206 Country of ref document: BR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23772393 Country of ref document: EP Kind code of ref document: A1 |